Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche to begin further phase III trials of Avastin

Roche to begin further phase III trials of Avastin

6th May 2009

Roche will begin a global phase III trial of Avastin (bevacizumab) in patients with newly diagnosed glioblastoma.

This was asserted after it was announced today (May 6th) the treatment has been granted authorisation from the Food and Drug Administration for sufferers of the progressive disease prior to therapy.

The body voted unanimously and it was permitted under its accelerated approval programme, which allows temporary consent for medicines that are intended to help combat cancer or other life-threatening diseases.

Dr Timothy Cloughesy, from the University of California, explained there has not been a new remedy for patients with this particular type of brain cancer for over ten years.

“After so many years with little progress in this field, Avastin was associated with a durable tumour response and doctors now have a new medicine to offer patients,” he said.

Chief executive officer of Roche’s pharmaceutical division William M Burns noted the approval would not have been possible without the work of physicians and people who took part in the clinical trials.

Headquartered in Basel, Switzerland, the company now employs around 80,000 staff and sells its products in more than 150 countries.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.